Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Alkermes plc

Alkermes plc (ALKS) Stock Overview

Explore Alkermes plc’s financial performance, market position, analyst ratings, and future outlook.

ALKS●NASDAQ
HealthcareBiotechnology
$49.83
$0.30(0.60%)
U.S. Market is Open · 15:10

Alkermes plc (ALKS)

Meyka AI Score

Z

Key Financials

Market Cap8.3B
P/E Ratio123.03
EPS (TTM)$0.95
ROE0.04%
Fundamental Analysis

AI Price Forecasts

1 Month$52.76
3 Months$59.20
1 Year Target$37.91

ALKS Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Alkermes plc (NASDAQ: ALKS) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Alkermes plc's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of ALKS on the NASDAQ shows an RSI of 45.99, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $37.91 for the NASDAQ listing.

Key metrics behind Alkermes plc's NASDAQ-traded stock include a P/E ratio of 123.03 and a market capitalization of 8.3B. Combined with our AI analysis, these give both institutional and retail investors a clear view of ALKS on the NASDAQ.

Price Performance (NASDAQ: ALKS)

1-Day Change
0.28%
5-Day Change
3.80%
1-Month Change
-9.92%
3-Month Change
45.36%
6-Month Change
45.53%
Year-to-Date (YTD) Change
77.52%
1-Year Change
86.45%
3-Year Change
79.96%
5-Year Change
77.58%
All-Time (Max) Change
803.09%

Contact Information

http://www.alkermes.com
353 1 772 8000
Connaught House, Dublin, DU, D04 C5Y6

Company Facts

20,500 Employees
IPO DateJul 16, 1991
CountryIE
Actively Trading

Frequently Asked Questions